Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rimma Gelbert

Family Medicine Brooklyn, NY Doctor of Osteopathy

NPI 1679642565 CMS profile 167107

1632 E 16Th St, Brooklyn, NY 11229

Open in the dashboard

General payments

$7,948

389 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rimma Gelbert of Brooklyn, NY is reported in the CMS Open Payments database as having received $7,948 across 389 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $997 45
2024 General $1,396 62
2023 General $1,492 65
2022 General $1,446 73
2021 General $1,056 57
2020 General $493 28
2019 General $1,066 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rimma Gelbert
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Rimma Gelbert were reported at $997. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Rimma Gelbert Family Medicine median Middle half National median
2019 $1,066 $150 $41–$543 $163
2020 $493 $120 $32–$415 $114
2021 $1,056 $137 $35–$551 $132
2022 $1,446 $137 $37–$512 $149
2023 $1,492 $149 $42–$545 $160
2024 $1,396 $156 $44–$560 $164
2025 $997 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,726 84 payments
  2. Novo Nordisk Inc $831 42 payments
  3. Horizon Therapeutics plc $577 28 payments
  4. Amgen Inc. $564 27 payments
  5. Lilly USA, LLC $510 26 payments
  6. Amarin Pharma Inc. $408 20 payments
  7. Astellas Pharma US Inc $240 13 payments
  8. Exact Sciences Corporation $232 9 payments
  9. Ardelyx, Inc. $215 7 payments
  10. Sumitomo Pharma America, Inc. $200 10 payments
  11. Other $2,445 123 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,948 389 payments
Products named General payments · program years 2019–2025
  1. Ozempic $751 38 payments
  2. CREON $680 40 payments
  3. UBRELVY $608 26 payments
  4. LINZESS $537 33 payments
  5. RYBELSUS $513 26 payments
  6. PENNSAID $452 27 payments
  7. QULIPTA $358 14 payments
  8. Repatha $341 16 payments
  9. GEMTESA $325 15 payments
  10. Vascepa $318 15 payments
  11. Other $5,371 268 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 212 drugs

Part D claims

18,042

Median for Family Practice: 1,826

Drug cost

$3,113,382

Median for Family Practice: $120,094

Branded share of claims

36.9%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vascepa Icosapent Ethyl Brand 775 $286,356
Zenpep Lipase/Protease/Amylase Brand 194 $217,439
Mounjaro Tirzepatide Brand 206 $214,625
Diclofenac Sodium Generic 420 $213,591
Creon Lipase/Protease/Amylase Brand 186 $212,590
Linzess Linaclotide Brand 369 $197,362
Ozempic Semaglutide Brand 162 $156,729
Eliquis Apixaban Brand 225 $149,299
Repatha Sureclick Evolocumab Brand 223 $129,208
Jardiance Empagliflozin Brand 192 $115,355

The 10 drugs with the highest cost, of 212 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$613,047

Of which drugs: $8,485

Medicare patients

422

Average age 75

Services billed

12,114

312 women, 110 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Arthritis 72%
Ischemic heart disease 39%
Depression 39%
Osteoporosis 32%
Heart failure 22%
Chronic kidney disease 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 74 74 $6,015
Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older 90732 Office 14 14 $1,831
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 115 461 $446
Infusion, normal saline solution, 250 cc J7050 Office 31 147 $71
Injection, ketorolac tromethamine, per 15 mg J1885 Office 22 100 $57

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $160
$160 13 —
IBSRELA
  • Ardelyx, Inc. $157
$157 — —
CREON
  • AbbVie, Inc. $123
$123 186 —
LINZESS
  • AbbVie, Inc. $73
  • Ironwood Pharmaceuticals, Inc $49
$122 369 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $103
$103 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

389 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record